Literature DB >> 9813160

Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner.

Y Kobayashi1, S Miwa, D E Merry, A Kume, L Mei, M Doyu, G Sobue.   

Abstract

Spinal and bulbar muscular atrophy (SBMA) is one of a group of human inherited neurodegenerative diseases caused by polyglutamine expansion. There is increasing evidence that generation of truncated proteins containing an expanded polyglutamine tract may be an important step in the pathogenesis of these disorders. We have previously demonstrated that the SBMA gene product, the androgen receptor (AR) protein, is toxic when truncated. We now report that in vitro translated full-length AR proteins containing different sized polyglutamine repeats (24, 65 and 97 repeats, respectively) are specifically cleaved by recombinant caspase-3, liberating a polyglutamine containing fragment, and that the susceptibility to cleavage is polyglutamine repeat length-dependent. These findings suggest that AR protein is one of the "death substrates" cleaved by caspase-3 and that caspase-3 might be involved in the pathogenesis of SBMA. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813160     DOI: 10.1006/bbrc.1998.9624

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Nutrient deprivation induces neuronal autophagy and implicates reduced insulin signaling in neuroprotective autophagy activation.

Authors:  Jessica E Young; Refugio A Martinez; Albert R La Spada
Journal:  J Biol Chem       Date:  2008-11-18       Impact factor: 5.157

Review 2.  Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease.

Authors:  Dagmar E Ehrnhoefer; Liza Sutton; Michael R Hayden
Journal:  Neuroscientist       Date:  2011-02-10       Impact factor: 7.519

3.  Histone deacetylase inhibitors reduce polyglutamine toxicity.

Authors:  A McCampbell; A A Taye; L Whitty; E Penney; J S Steffan; K H Fischbeck
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

Review 4.  Androgen receptor mutation in Kennedy's disease.

Authors:  K H Fischbeck; A Lieberman; C K Bailey; A Abel; D E Merry
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 5.  The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review.

Authors:  R Walsh; E Storey; D Stefani; L Kelly; V Turnbull
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 6.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

7.  Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor.

Authors:  V Panet-Raymond; B Gottlieb; L K Beitel; H Schipper; M Timiansky; L Pinsky; M A Trifiro
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

Review 8.  Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.

Authors:  Masahisa Katsuno; Hiroaki Adachi; Fumiaki Tanaka; Gen Sobue
Journal:  J Mol Med (Berl)       Date:  2004-02-27       Impact factor: 4.599

9.  Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk.

Authors:  Jessica E Young; Gwenn A Garden; Refugio A Martinez; Fumiaki Tanaka; C Miguel Sandoval; Annette C Smith; Bryce L Sopher; Amy Lin; Kenneth H Fischbeck; Lisa M Ellerby; Richard S Morrison; J Paul Taylor; Albert R La Spada
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

Review 10.  Neuropathology and therapeutic intervention in spinal and bulbar muscular atrophy.

Authors:  Haruhiko Banno; Masahisa Katsuno; Keisuke Suzuki; Fumiaki Tanaka; Gen Sobue
Journal:  Int J Mol Sci       Date:  2009-03-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.